SIGA Technologies

NASDAQ: SIGA

Market Cap$670m

Last Close $9.18

SIGA Technologies is focused on the treatment of smallpox and other orthopoxviruses. It has contracts with the US and Canadian governments for TPOXX, its treatment for smallpox and is looking to expand internationally. As the leading smallpox therapeutic manufacturer, SIGA is likely to remain a beneficiary through the monkeypox epidemic.

More SIGA Technologies content >

Investment summary

SIGA Technologies is a commercial-stage company focused on the treatment of smallpox and other orthopoxvirus. Lead drug TPOXX was approved by the US FDA in 2018 for the treatment of smallpox and in the EU and UK under the broad label including all orthopox pathogens in 2022. In addition, three randomized, placebo-controlled trials were launched in October 2022 to assess the safety and efficacy of TPOXX in treating patients with monkeypox. The near-term outlook seems positive with upcoming BARDA contract-related deliveries for oral and IV TPOXX and upside optionality from additional/recurring government contracts.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (fd) (c)
P/E (x)
P/CF (x)
2020A 125.0 88.6 81.5 80.97 11.3 10.1
2021A 133.7 89.7 89.1 90.61 10.1 59.9
2022E 115.4 47.6 47.1 48.35 19.0 18.3
2023E 169.0 89.1 88.5 94.51 9.7 26.0
Industry outlook

With about 64k global cases and 23k cases in the United States, monkeypox remains a growing concern for governments and health agencies. SIGA’s antiviral product TPOXX is the leading therapeutic, originally designed to treat smallpox. In the United States, TPOXX was approved by the FDA for smallpox and is now available to treat monkeypox through the Centers for Disease Control and Prevention’s expanded access investigational new drug protocol. Currently, it is the only allowed therapy for all orthopoxvirus pathogens, including monkeypox, approved in both the UK (July 2022) and the EU (January 2022).

Last updated on 30/11/2022
Content on SIGA Technologies
SIGA Technologies – Solid Q322, underpinned by international traction
Healthcare | research Update | 4 November 2022
covid-19-4987797
SIGA Technologies – TPOXX trials launched in treating monkeypox
Healthcare | research Flash note | 14 October 2022
covid-19-4987797
SIGA Technologies – executive interview
Healthcare | Edison TV | 7 October 2022
View more
Register to receive research on SIGA Technologies as it is published
Share price graph
Balance sheet
Forecast net cash (US$m) 106.8
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (0.6) (42.7) 12.8
Relative* (2.1) (41.7) 32.7
52-week high/low US$26.1/US$6.0
*% relative to local index
Key management
Phillip Gomez CEO
Daniel Luckshire Executive VP and CFO

You may also be interested in…